Intravenous Drug Abuse Clinical Trial
Official title:
Optimizing Bio-behavioral HIV Prevention Approaches for People Who Inject Drugs
Verified date | March 2021 |
Source | Boston University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID, yet uptake has been low in this population and uptake and adherence interventions have not been developed or tested. Drawing from formative qualitative research, the overall goal of this project is to develop an intervention to promote PrEP uptake and adherence among PWID in the U.S. Northeast. The investigators will: - Analyze existing literature and data to identify specific barriers and facilitators to PrEP uptake and adherence among PWID to inform the initial adaptation of existing theory-based interventions; - Conduct qualitative interviews with ~30 PWID and ~10 key informants (PrEP and other clinical and social service providers) to identify intervention targets; - Develop and iteratively refine and finalize an intervention manual based on feedback from qualitative exit-interviews with an interventionist and ~10 PWID; and - Conduct a pilot randomized clinical trial (RCT) in ~50 HIV-uninfected PWID to compare PrEP uptake and adherence outcomes and assess intervention feasibility and acceptability.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2022 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | For all phases: Inclusion Criteria: - An adult PWID - Self report of any high risk behaviors for HIV (past-month receptive syringe sharing, transactional sex, condomless sex with an HIV-infected or unknown status partner) Exclusion Criteria: - Unable or unwilling to provide informed consent For Phase 3 (the RCT pilot): Inclusion Criteria: - Clinically eligible for PrEP (confirmed HIV-uninfected status, adequate renal function [estimated creatinine clearance =60 ml/min], and documented hepatitis B virus [HBV] status) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Boston University | National Institute on Drug Abuse (NIDA) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PrEP uptake by self-report | measured using 1 item in a structured questionnaire | 1 month | |
Primary | PrEP uptake by self-report | measured using 1 item in a structured questionnaire | 3 months | |
Primary | PrEP uptake by pharmacy records | measured by accessing pharmacy records | 1 month | |
Primary | PrEP uptake by pharmacy records | measured by accessing pharmacy records | 3 months | |
Primary | PrEP adherence by self-report | measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed | 1 month | |
Primary | PrEP adherence by self-report | measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed | 3 months | |
Primary | PrEP adherence by dried blood spot | measured via detection of tenofovir and emtricitabine in dried blood spots (DBS) | 1 month | |
Primary | PrEP adherence by dried blood spot | measured via detection of tenofovir and emtricitabine in dried blood spots (DBS) | 3 months | |
Secondary | Participant satisfaction with intervention content | assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful) | 1 month | |
Secondary | Participant satisfaction with intervention delivery methods | assessed via qualitative exit interviews exploring satisfaction with the intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were) | 1 month | |
Secondary | Interventionist satisfaction with training materials | assessed via qualitative exit interviews exploring satisfaction with the training materials for interventionists (including an open-ended question on how helpful or unhelpful the training materials were) | 1 month | |
Secondary | Interventionist satisfaction with intervention manual | assessed via qualitative exit interviews exploring satisfaction with the intervention manual (including an open-ended question on how helpful or unhelpful the intervention manual was) | 1 month | |
Secondary | Interventionist satisfaction with intervention content | assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful) | 1 month | |
Secondary | Interventionist satisfaction with intervention delivery methods | assessed via qualitative exit interviews exploring satisfaction with the training materials, intervention manual, intervention content, intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were) | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00844272 -
Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment
|
Phase 4 | |
Completed |
NCT01128920 -
Reducing Health Problems Associated With Injection Drug Use
|
N/A |